The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Hopefully by end of the week. Hold for Gold!!! good luck
Moving back up now good luck all
To fellow alba investors pls ignore what people say on the board. Do your research yourself and stick to it. If you believe in then invest like i have done and stay calm and be patient. You will be handsomly rewarded. Gla
Nookie.. I Think share trading is not for you. You should sell up and move on otherwise remain patient. Good things come to those who wait.
Which other company on aim do you know of that has been visited by itv? Surely that should tell you this is a special one. Anyways you guys need to be patient and not cry over daily fluctuations. No share can keep rising each and every day so be realistic and set a target foe where you see the share price in few months time. Look at the bigger picture. Also warrants are being churned which has impacted the sp. Alba wouldnt be buying specialist equipment if there was nothing there. Personally i believe we will see multiples of this share price n a few months time. Keep the faith and hold for gold!
Should start to move back up again and hopefully reach new highs as things start to unfold. All the ducks are lining up nicely. The rerate has just begun! Gla
https://www.letsrecycle.com/news/latest-news/energy-from-waste-could-become-worse-than-landfill/
No thanks...id rather stick to what i know. That is Alba ordered gold processing plant for obvious reasons. Gla
Hunter i get a fixed quote for shares purchased less than 990000. If i buy more it goes to nt. Try that gla
Just bought some more 2500000 shares at 0.38p couldn't resist it. Gla
For those who may have missed this https://youtu.be/KysCulRjFew
Thanks alot
Hi guys just looking to buy some kibo shares but would really appreciate it if you could advise why sp has dropped so much from june 2020. Thanks in advance ..Mit
DDDD added 50m to mcap when Thier percentage rate was 42% val 201 is 54%
Very impressive results in this heavily treated population
The real result is for cancer patients with prostate cancer.
Well done @DillySuzy & the team
The headline results, detailed below, provide a summary of the top-level data of safety and tolerability as well as evidence for disease impact as observed during the clinical trial. Full data and details of from the clinical trial are expected to be received by the Company by end Q4 2020.
Disease Impact - Overall Response Rate 54.5%
Evidence for positive disease impact has been measured using PCWG2 (Prostate Cancer Working Group 2) guidelines. These industry standard guidelines take into account both the primary tumour and metastatic tumours alongside prostate specific antigen (PSA) levels to assess whether the disease has progressed, or whether the patient has responded and halted disease progression. These guidelines provide a more comprehensive measure of disease impact than just primary tumour imaging.
Of the 12 patients dosed with VAL201, 11 patients had sufficient PCWG2-relevant data collected across multiple cycles. 6 of these 11 have been categorised as responding throughout treatment. That is, when the treatment with VAL201 was halted for a defined reason, whether or not the 6 standard cycles had been completed, these patients showed no disease progression by PCWG2 criteria with stable disease.
Safety and Tolerability - no Maximum Tolerated Dose declared